Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
The introduction of biologics for the treatment of patients with refractory asthma represented a marked therapeutic advance. For more than 10 y, the only biologic available has been the monoclonal anti-IgE antibody omalizumab, reserved for patients with asthma caused by perennial allergen. In recent...
Na minha lista:
Principais autores: | , , , , , , |
---|---|
Formato: | Livro |
Publicado em: |
Taylor & Francis Group,
2020-10-01T00:00:00Z.
|
Assuntos: | |
Acesso em linha: | Connect to this object online. |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
Internet
Connect to this object online.3rd Floor Main Library
Número de Chamada: |
A1234.567 |
---|---|
Cópia 1 | Disponível |